Application of 2,4,6-Trichloro-1,3,5-Triazine (TCT) Supported on Graphene Oxide Nanosheet Decorated with Pd Nanoparticles (Pd/TCT-GO) in Chemotherapy: A Nanocarrier for Mitomycin C and Methotrexate
نویسندگان
1 Bukhara State Pedagogical Institute, Bukhara, Uzbekistan
2 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
3 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
4 Samarkand State Medical University, Samarkand, Uzbekistan
5 Jizzakh Polytechnic Institute, Jizzakh, Uzbekistan
6 Chirchik State Pedagogical University, Uzbekistan
7 Urgench State University, Urgench, Uzbekistan
8 Tashkent State Technical University, Tashkent, Uzbekistan
9 Tashkent State Medical University, Tashkent, Uzbekistan
10 Termez State Pedagogical Institute, Termez, Uzbekistan
11 .Mamun University, Khiva, 220900, Uzbekistan
12 Jizzakh State Pedagogical university, Jizzakh, Uzbekistan
13 Tashkent State University of Economics, Tashkent, Uzbekistan
doi
10.22052/JNS.2025.03.044چکیده
This study presents the synthesis, characterization, and biomedical application of a novel nanocarrier system, Pd/TCT-GO, designed for targeted chemotherapy. The nanocomposite was prepared through a stepwise process involving the functionalization of graphene oxide (GO) with 2,4,6-trichloro-1,3,5-triazine (TCT) and subsequent decoration with palladium (Pd) nanoparticles. Characterization techniques, including FE-SEM and FT-IR, confirmed the successful synthesis with uniform Pd nanoparticle distribution and effective surface modification. The nanocarrier demonstrated remarkable drug-loading capacities, achieving over 85% encapsulation efficiency for both Mitomycin C and Methotrexate, with sustained release profiles extending up to 48 hours. In vitro studies revealed controlled biphasic drug release, with approximately 85% and 78% of MMC and MTX released, respectively. The multifunctional platform exploits the catalytic activity of Pd and the surface chemistry of TCT and GO, facilitating targeted delivery and controlled release. Comparative analyses highlight its superiority over existing nanocarriers in terms of stability, loading capacity, and release kinetics. Addressing current challenges, future work will focus on improving biocompatibility and targeting efficiency, aiming to translate this promising nanoplatform into clinical oncology applications.
